Gabather gets SEK 10 mln for development of drug candidate GT-002

Friday, Sep 30, 2016

Gabather AB Says has signed a consortium agreement for clinical development of its drug candidate GT-002 together with partner companies Pharmaterials, Smerud and CRST.

Cooperation starts in October and lasts until Phase 2a or a total of three years.

The agreement gives a net contribution from local EU authorities to cooperation of about 10 million Swedish crowns ($1.16 million).

Other costs are paid by the participating parties.


Source :

Other News